Replies to post #49491 on Biotech Values

[DewDiligence]

Lucentis has a 55% share of NRx’s and a 50% share of TRx’s, which is unchanged from the prior quarter. As a matter of policy, DNA won’t comment on the progress of the head-to-head study sponsored by NIH.